A narrative review examines the complex health challenges faced by people who have received kidney transplants. The analysis highlights that metabolic syndromes, which include conditions like high blood pressure and abnormal cholesterol, develop in 30% to 50% of these patients during their first year after the procedure. These metabolic issues are often linked to diabetes and other disorders that can affect the new organ.
The review also identifies antibody-mediated rejection as a leading cause of graft failure later on. This type of rejection involves the immune system attacking the transplanted kidney. The authors note a bidirectional relationship between immune injury and metabolic dysregulation, suggesting these problems influence each other.
New medications, such as complement inhibitors and SGLT2 inhibitors, are being studied for their potential benefits. However, the data on their long-term efficacy remain limited. Because the evidence is based on a review rather than a specific clinical trial, readers should be cautious about expecting immediate changes in practice. Integrated immunometabolic strategies are essential for optimizing graft and patient survival, but more research is needed to confirm the long-term safety and effectiveness of these novel agents.
